All RPE65‐associated retinal dystrophy patients who have sufficient viable retinal cells with confirmed biallelic mutations in the RPE65 gene, including patients with UPiD, are eligible for VN therapy. This evidence concerns the gene RPE65 and inherited retinal dystrophy.